Full-Year Revenue and Subscription Mix
Total revenue for fiscal 2025 was $249.3 million. Subscription revenue grew to represent 53% of total revenue, up from 45% in 2024, reflecting a deliberate shift to higher-quality, recurring SaaS revenue.
Material Reduction in Losses and Cost Base
The company reduced both net loss and adjusted EBITDA losses by approximately $100 million for the full year 2025 driven by disciplined cost actions and restructuring.
Operating Expense Improvement and Adjusted EBITDA Progress
Fourth-quarter operating expenses (ex D&A) declined 30.7% year-over-year and operating expenses as a percentage of revenue improved to 96.7% from 108.7% the prior year. Adjusted EBITDA loss improved to $(10.3) million in the quarter (an improvement vs prior periods).
Commercial Momentum and Contract Renewals
Strong commercial traction in 2025 included over 15 payer contract renewals representing the majority of payer subscription revenue, Blue Cross Blue Shield of Florida going live in January, and a multi-year renewal with Elevance.
Platform Transformation and Strategic Focus
Company completed transformation from telehealth provider to a focused technology-enabled care platform, divested noncore activities (e.g., APC), and prioritized AI-enabled clinical programs and vendor consolidation to increase revenue quality and stickiness.
Healthy Balance Sheet and Debt-Free Position
Ended the year with approximately $182 million in cash and marketable securities and no debt, and reported quarterly cash burn of ~$19 million, providing runway while pursuing breakeven.
Forward Guidance Toward Operational Breakeven
Provided FY2026 guidance of $195.0M–$205.0M revenue and expects positive cash flow from operations in Q4 2026, with FY2026 adjusted EBITDA loss guidance of $(24.0)M to $(18.0)M and Q1 2026 adjusted EBITDA loss of $(7.0)M to $(5.0)M.